Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
Quick Reference
Administration Method
Subcutaneous injection once weekly
Step-by-Step Dosing Protocol
Dosing Guidelines
Clinical protocols typically begin with 0.3 mg weekly for 4 weeks, followed by gradual escalation to 0.6 mg, 1.2 mg, 1.8 mg, and maximum 2.4 mg weekly at 4-week intervals. For combination therapy (CagriSema), cagrilintide is typically dosed at 1.2-2.4 mg weekly alongside semaglutide 1.0-2.4 mg weekly. Dose escalation should be individualized based on tolerability and weight loss response.
Like other weight loss peptides, you start low and increase slowly with Cagrilintide. Most people start with 0.3mg once a week and increase by small amounts every month until they reach their optimal dose, usually 1.2-2.4mg per week. When combined with semaglutide in CagriSema, both medications are typically used at their effective doses to maximize the benefits of both pathways working together.
Mixing & Injection
Subcutaneous injection using pre-filled pens or vials with insulin syringes. Injection sites include abdomen, thigh, or upper arm, with site rotation to prevent lipodystrophy. Administer on the same day each week, preferably at the same time. Can be taken with or without food. If a dose is missed, administer as soon as possible within 3 days, otherwise skip and resume regular schedule. When used in combination with semaglutide, separate injection sites are recommended.
Subcutaneous injection using pre-filled pens or vials with insulin syringes. Injection sites include abdomen, thigh, or upper arm, with site rotation to prevent lipodystrophy. Administer on the same day each week, preferably at the same time. Can be taken with or without food. If a dose is missed, administer as soon as possible within 3 days, otherwise skip and resume regular schedule. When used in combination with semaglutide, separate injection sites are recommended.
Clinical Administration Guidelines
Injection Protocol
- •Subcutaneous injection once weekly
- •Rotate between abdomen, thigh, upper arm
- •Same day each week, any time of day
- •Can be taken with or without food
Monitoring Schedule
- •Weekly weight measurements
- •Monthly HbA1c (if diabetic)
- •Quarterly lipid panels
- •Regular blood pressure monitoring
Dosage Calculator
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.